Subscribe

Abbott Laboratories (ABT)

USD92.12 -1.82 (-1.93%)
US NYSE S&P 500 Healthcare Medical - Devices
Address 100 Abbott Park Road 60064-6400
Abbott Park, IL, US
CEO Robert Ford
Website abbott.com
IPO 1980-03-17
CIK 1800 ISIN US0028241000

Explore sections of this company profile

Also trades on Deutsche Börse · ABL.DE (EUR) New York Stock Exchange · ABT (USD) Swiss Exchange · ABT.SW (CHF)
Description

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
ALZA AZA 1999-08-16 View
Perclose 1999-08-25 View
2007840 STJ 2016-06-13 View

Index membership

IndexAddedRemovedStatus
S&P 500 1957-03-04 Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD92.12 -1.82 (-1.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13M
Beta
0.62
Float Shares
1.73B
Free Float %
99.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.83% -1.44% -5.74% -26.45% -33.61% -31.69% -35.93% -15.86% -19.10% +115.95% +51,876.92%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (41 ratings, all time) Buy
Price Targets & DCF
Current price
92.12
Low 92.00 -0.1%
Consensus 127.46 +38.4%
Median 125.00 +35.7%
High 152.00 +65.0%
DCF (Unlevered) 150.36 +63.2%
DCF (Levered) 128.15 +39.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 75% Bullish
Rating 2026-05 Change
Strong Buy 5 -1
Buy 16 0
Hold 7 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month
Last Quarter 7
126.86
+37.7%
Last Year 25
137.92
+49.7%
All Time 70
132.83
+44.2%
Quality scores
Altman Z-Score
2.95
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Devices: +11.2%
    +5.7% Q1'26: +7.8% (vs Q1'25)
  • EPS growth Medical - Devices: +28.5%
    -51.3% Q1'26: -18.2% (vs Q1'25)
  • FCF margin FCF growth · Medical - Devices: +30.9%
    +14.2% Q1'26: +8.2% (vs Q1'25)
  • EBIT margin Medical - Devices: +6.2%
    +19.9% Q1'26: +16.5% (vs Q1'25)
  • ROIC Medical - Devices: +3.3%
    +11.5% Q1'26: +6.9% (vs Q1'25)
  • Share dilution Medical - Devices: 0.0%
    -0.1% Q1'26: 0.0% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    1.30× Q1'26: 4.62× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.65) × ERP
WACC = 91% × Ke + 9% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Intrinsic value (base): 150.36 Current price: 92.12
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual
Dec 2012
actual
Dec 2013
actual
Dec 2014
actual
Dec 2015
actual
Dec 2016
actual
Dec 2017
actual
Dec 2018
actual
Dec 2019
actual
Dec 2020
actual
Dec 2021
actual
Dec 2022
actual
Dec 2023
actual
Dec 2024
actual
Dec 2025
actual
Dec 2026
19 Rev. Ana.
16 EPS Ana.
Dec 2027
19 Rev. Ana.
16 EPS Ana.
Dec 2028
18 Rev. Ana.
9 EPS Ana.
Dec 2029
11 Rev. Ana.
3 EPS Ana.
Dec 2030
9 Rev. Ana.
3 EPS Ana.
Revenue
38.85B
est: 38.51B (+0.9%)
39.87B
est: 39.30B (+1.5%)
21.85B
est: 21.09B (+3.6%)
20.25B
est: 19.77B (+2.4%)
20.41B
est: 20.44B (-0.2%)
20.85B
est: 20.89B (-0.2%)
27.39B
est: 27.20B (+0.7%)
30.58B
est: 30.67B (-0.3%)
31.90B
est: 31.86B (+0.1%)
34.61B
est: 33.85B (+2.2%)
43.08B
est: 42.32B (+1.8%)
43.65B
est: 43.22B (+1.0%)
40.11B
est: 40.73B (-1.5%)
41.95B
est: 42.00B (-0.1%)
44.33B
est: 44.67B (-0.8%)
50.40B
50.35B – 50.49B
+12.8% YoY
54.94B
54.15B – 55.36B
+9.0% YoY
58.93B
58.81B – 59.04B
+7.2% YoY
63.43B
61.43B – 63.86B
+7.7% YoY
68.25B
66.09B – 68.71B
+7.6% YoY
EBITDA
9.26B
est: 8.70B (+6.5%)
3.50B
est: 9.49B (-63.2%)
3.60B
est: 4.41B (-18.4%)
4.16B
est: 4.47B (-7.1%)
4.83B
est: 6.20B (-22.1%)
3.07B
est: 3.45B (-11.0%)
6.13B
est: 6.01B (+2.1%)
6.88B
est: 6.93B (-0.8%)
7.91B
est: 7.66B (+3.3%)
9.00B
est: 7.71B (+16.8%)
12.16B
est: 10.02B (+21.3%)
11.89B
est: 10.75B (+10.6%)
10.61B
est: 10.90B (-2.7%)
10.83B
est: 11.24B (-3.6%)
11.55B
est: 11.95B (-3.3%)
13.49B
13.47B – 13.51B
+12.8% YoY
14.70B
14.49B – 14.81B
+9.0% YoY
15.77B
15.74B – 15.80B
+7.2% YoY
16.97B
16.44B – 17.09B
+7.7% YoY
18.26B
17.68B – 18.38B
+7.6% YoY
EBIT
6.22B
est: 5.70B (+9.0%)
714.00M
est: 7.97B (-91.0%)
2.09B
est: 2.54B (-17.7%)
2.68B
est: 2.59B (+3.6%)
3.36B
est: 2.74B (+22.7%)
1.72B
est: 3.11B (-44.8%)
3.11B
est: 1.72B (+80.8%)
3.60B
est: 3.61B (-0.4%)
4.90B
est: 4.48B (+9.3%)
5.68B
est: 4.73B (+20.0%)
8.62B
est: 6.83B (+26.2%)
8.62B
est: 8.03B (+7.3%)
7.36B
est: 7.83B (-6.0%)
7.62B
est: 8.08B (-5.7%)
8.81B
est: 8.59B (+2.5%)
9.69B
9.68B – 9.71B
+12.8% YoY
10.56B
10.41B – 10.65B
+9.0% YoY
11.33B
11.31B – 11.35B
+7.2% YoY
12.20B
11.81B – 12.28B
+7.7% YoY
13.12B
12.71B – 13.21B
+7.6% YoY
Net Income
4.73B
est: 4.69B (+0.9%)
5.96B
est: 5.87B (+1.5%)
2.58B
est: 2.47B (+4.5%)
2.28B
est: 2.14B (+6.9%)
4.42B
est: 4.10B (+8.0%)
1.40B
est: 1.37B (+2.5%)
477.00M
est: 425.71M (+12.0%)
2.37B
est: 2.34B (+1.2%)
3.69B
est: 3.64B (+1.3%)
4.50B
est: 3.98B (+12.9%)
7.07B
est: 5.75B (+23.0%)
6.93B
est: 6.73B (+3.0%)
5.72B
est: 5.54B (+3.4%)
13.40B
est: 8.17B (+64.1%)
6.52B
est: 9.00B (-27.5%)
9.57B
9.55B – 9.60B
+6.3% YoY
10.58B
10.42B – 10.74B
+10.5% YoY
9.23B
8.68B – 13.67B
-12.7% YoY
13.21B
12.66B – 13.32B
+43.1% YoY
14.60B
14.00B – 14.73B
+10.5% YoY
SGA
12.54B
est: 12.64B (-0.8%)
7.30B
est: 11.88B (-38.5%)
6.34B
est: 6.68B (-5.1%)
6.29B
est: 6.29B (-0.1%)
6.64B
est: 6.45B (+3.0%)
6.64B
est: 6.49B (+2.2%)
8.96B
est: 8.73B (+2.6%)
9.69B
est: 9.63B (+0.6%)
9.69B
est: 9.62B (+0.7%)
9.67B
est: 8.21B (+17.8%)
11.28B
est: 9.34B (+20.7%)
11.11B
est: 9.00B (+23.4%)
10.88B
est: 10.95B (-0.6%)
11.65B
est: 11.29B (+3.2%)
12.38B
est: 12.01B (+3.0%)
13.55B
13.54B – 13.58B
+12.8% YoY
14.77B
14.56B – 14.89B
+9.0% YoY
15.85B
15.82B – 15.88B
+7.2% YoY
17.06B
16.52B – 17.17B
+7.7% YoY
18.35B
17.77B – 18.48B
+7.6% YoY
EPS
3.01
est: 4.58 (-34.3%)
3.78
est: 4.93 (-23.3%)
1.66
est: 1.87 (-11.2%)
1.51
est: 2.00 (-24.5%)
3.00
est: 2.15 (+39.6%)
0.95
est: 2.20 (-56.9%)
0.27
est: 2.50 (-89.2%)
1.35
est: 2.88 (-53.2%)
2.07
est: 3.24 (-36.2%)
2.52
est: 3.55 (-29.0%)
3.97
est: 5.10 (-22.1%)
3.94
est: 5.23 (-24.7%)
3.30
est: 3.18 (+3.8%)
7.67
est: 4.67 (+64.1%)
3.74
est: 5.15 (-27.4%)
5.47
5.46 – 5.49
+6.2% YoY
6.06
5.97 – 6.14
+10.6% YoY
6.75
4.97 – 7.83
+11.5% YoY
7.56
7.25 – 7.63
+11.9% YoY
8.36
8.01 – 8.43
+10.5% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-04-27 BTIG Buy Buy Maintain
2026-04-20 Barclays Overweight Overweight Maintain
2026-04-17 Piper Sandler Overweight Overweight Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-27 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-26 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-22 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-21 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-20 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-19 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-18 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-15 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-14 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-05-13 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-12 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-11 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-08 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-07 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-06 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-05 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-04 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-05-01 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-04-30 B 3/5 4/5 4/5 4/5 1/5 2/5 2/5
2026-04-29 B 3/5 4/5 3/5 4/5 1/5 2/5 3/5
2026-04-28 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-27 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-24 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-23 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-22 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-21 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-20 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-17 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-16 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5
2026-04-15 B+ 3/5 4/5 4/5 5/5 1/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
8.13B
OE per share TTM
4.65
Owner's Yield
5.44%
Maintenance CapEx ratio
16.86%
Maint CapEx / Avg PPE
27.0%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
3,144
Total invested
141.24B
Insider transactions (90d)
15
Beneficial owners (>5%)
14
Beneficial owners (>5%)
# Reporting person Amount owned % of class Sole voting Shared voting Sole dispositive Shared dispositive Type Citizenship Filing date SEC filing
1 The Vanguard Group - 23-1945930 149.15M 8.43% 2.88M 141.95M 7.20M IA 2022-02-09
2 (1) BlackRock, Inc. 137.16M 7.80% 121.11M HC Delaware 2022-02-01
3 Capital Research Global Investors ** 113.69M 6.40% 113.69M 113.69M IA Delaware 2020-02-14
4 ###-##-#### 92.77M 5.60% 92.50M 92.50M 92.50M IN United States 2003-02-05
5 BlackRock for purposes of Schedule 13G filings. 91.72M 5.93% 91.72M 91.72M HC Delaware 2010-01-29
6 Abbott Laboratories Stock Retirement Trust 89.28M 5.40% 89.28M EP Illinois 2003-02-05
7 Amber Acquisition Inc. 81.91M 100.00% 81.91M 10.00 CO Delaware 2010-04-21
8 Rainforest Acquisition Inc. 9.64M 15.50% 9.64M 10.00 CO Delaware 2009-01-21
9 Abbott Investments Luxembourg Sarl 2.50M 29.60% 2.50M 10.00 CO Luxembourg 2009-12-23
10 Scorpio Designated Corporation Ltd. 2.50M 29.60% 2.50M 10.00 CO Israel 2009-12-23
11 36-0698440 1.21M 2.93% 1.21M 1.21M 10.00 CO Illinois 2004-06-21
12 Abbott Laboratories 865.6K 1.70% 865.6K 865.6K CO State of Illinois 2014-02-14
13 95-1411037 13.00 4.90% 86.37M 86.39M IA Delaware 2021-02-16
14 Abbott Laboratories (36-0698440) 0.00% CO Illinois 2010-12-10

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
3,144
-197 vs prev Q
New positions
181
Closed positions
384
Increased
1,278
Reduced
1,426
Put/Call ratio
1.35
Calls held
6.98M
Puts held
9.39M
Top institutional holders
# Investor Shares / Δ Mkt value / Δ Own% / Δ Weight% / Δ Avg px / Perf. Hold / Status
1 VANGUARD GROUP INC 175.56M +2.4M (+1.4%) 22.00B -1.2B (-5.2%) 10.05% +0.149 pp 0.32% -0.028 pp USD52.43 +139.0% 84 qtrs
2 BLACKROCK, INC. 146.91M +5.3M (+3.8%) 18.41B -554.3M (-2.9%) 8.41% +0.315 pp 0.31% -0.021 pp USD115.13 +8.8% 6 qtrs
3 STATE STREET CORP 79.85M +1.6M (+2.1%) 10.00B -472.7M (-4.5%) 4.57% +0.098 pp 0.34% -0.028 pp USD54.72 +129.0% 51 qtrs
4 CAPITAL INTERNATIONAL INVESTORS 63.23M +1.6M (+2.6%) 7.92B -329.5M (-4.0%) 3.62% +0.097 pp 1.24% -0.090 pp USD90.08 +39.1% 51 qtrs
5 CAPITAL RESEARCH GLOBAL INVESTORS 39.17M +400.4K (+1.0%) 4.91B -285.2M (-5.5%) 2.24% +0.026 pp 0.91% -0.068 pp USD61.32 +104.3% 51 qtrs
6 GEODE CAPITAL MANAGEMENT, LLC 38.41M -134.4K (-0.3%) 4.79B -347.6M (-6.8%) 2.20% -0.005 pp 0.30% -0.032 pp USD69.71 +79.7% 78 qtrs
7 MORGAN STANLEY 36.73M -1.9M (-4.9%) 4.60B -573.2M (-11.1%) 2.10% -0.107 pp 0.27% -0.039 pp USD86.88 +44.2% 51 qtrs
8 NORGES BANK 23.46M +23.5M (+100.0%) 2.94B +2.9B (+100.0%) 1.34% +1.343 pp 0.31% +0.314 pp USD125.29 +0.0% 1 qtrs NEW
9 WELLINGTON MANAGEMENT GROUP LLP 23.43M +188.6K (+0.8%) 2.94B -177.4M (-5.7%) 1.34% +0.012 pp 0.51% -0.031 pp USD108.00 +16.0% 81 qtrs
10 JPMORGAN CHASE & CO 22.19M -7.2M (-24.5%) 2.78B -1.2B (-29.3%) 1.27% -0.410 pp 0.17% -0.061 pp USD110.45 +13.4% 51 qtrs
11 BANK OF AMERICA CORP /DE/ 19.83M -975.2K (-4.7%) 2.48B -302.2M (-10.8%) 1.14% -0.055 pp 0.18% -0.008 pp USD106.81 +17.3% 52 qtrs
12 NORTHERN TRUST CORP 19.78M -666.2K (-3.3%) 2.48B -260.3M (-9.5%) 1.13% -0.037 pp 0.32% -0.034 pp USD47.52 +163.7% 51 qtrs
13 T. ROWE PRICE INVESTMENT MANAGEMENT, INC. 17.89M +118.0K (+0.7%) 2.24B -138.9M (-5.8%) 1.02% +0.008 pp 1.41% -0.040 pp USD124.70 +0.5% 11 qtrs
14 WELLS FARGO & COMPANY/MN 16.29M -422.1K (-2.5%) 2.04B -197.4M (-8.8%) 0.93% -0.023 pp 0.37% -0.054 pp USD45.97 +172.5% 57 qtrs
15 GOLDMAN SACHS GROUP INC 15.50M -632.2K (-3.9%) 1.94B -218.7M (-10.1%) 0.89% -0.035 pp 0.24% -0.026 pp USD100.16 +25.1% 73 qtrs
16 PRICE T ROWE ASSOCIATES INC /MD/ 14.72M -1.1M (-6.8%) 1.84B -272.2M (-12.9%) 0.84% -0.061 pp 0.20% -0.028 pp USD126.81 -1.2% 75 qtrs
17 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 14.52M -577.6K (-3.8%) 1.82B -203.0M (-10.0%) 0.83% -0.032 pp 0.59% -0.040 pp USD72.81 +72.1% 51 qtrs
18 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 13.59M +— (+0.0%) 1.70B -117.5M (-6.5%) 0.78% +0.001 pp 1.34% -0.180 pp USD22.28 +462.3% 108 qtrs
19 INVESCO LTD. 13.34M -610.9K (-4.4%) 1.67B -197.2M (-10.6%) 0.76% -0.034 pp 0.26% -0.038 pp USD109.98 +13.9% 57 qtrs
20 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 13.19M +52.2K (+0.4%) 1.65B -107.1M (-6.1%) 0.76% +0.004 pp 0.26% -0.024 pp USD66.09 +89.6% 100 qtrs
21 AMERIPRISE FINANCIAL INC 13.18M -323.6K (-2.4%) 1.64B -159.3M (-8.8%) 0.75% -0.018 pp 0.37% -0.043 pp USD97.17 +28.9% 55 qtrs
22 BANK OF NEW YORK MELLON CORP 12.93M +247.7K (+2.0%) 1.62B -78.6M (-4.6%) 0.74% +0.015 pp 0.29% -0.042 pp USD80.28 +56.1% 66 qtrs
23 LEGAL & GENERAL GROUP PLC 12.62M -279.8K (-2.2%) 1.58B -146.6M (-8.5%) 0.72% -0.015 pp 0.35% -0.037 pp USD70.06 +78.8% 75 qtrs
24 ALLIANCEBERNSTEIN L.P. 12.45M +6.9M (+125.3%) 1.56B +820.0M (+110.8%) 0.71% +0.397 pp 0.49% +0.260 pp USD111.35 +12.5% 61 qtrs
25 NUVEEN, LLC 11.79M +140.2K (+1.2%) 1.48B -83.2M (-5.3%) 0.68% +0.009 pp 0.39% -0.025 pp USD132.56 -5.5% 4 qtrs
26 DEUTSCHE BANK AG\ 11.58M +934.8K (+8.8%) 1.45B +25.0M (+1.8%) 0.66% +0.054 pp 0.47% -0.005 pp USD101.54 +23.4% 50 qtrs
27 FISHER ASSET MANAGEMENT, LLC 11.44M -592.6K (-4.9%) 1.43B -178.3M (-11.1%) 0.65% -0.033 pp 0.49% -0.094 pp USD98.58 +27.1% 57 qtrs
28 FRANKLIN RESOURCES INC 11.16M +851.8K (+8.3%) 1.40B +18.3M (+1.3%) 0.64% +0.049 pp 0.34% -0.001 pp USD76.94 +62.8% 51 qtrs
29 UBS ASSET MANAGEMENT AMERICAS INC 11.06M +602.4K (+5.8%) 1.39B -15.0M (-1.1%) 0.63% +0.035 pp 0.29% -0.011 pp USD103.18 +21.4% 90 qtrs
30 UBS GROUP AG 10.48M +665.4K (+6.8%) 1.31B -1.5M (-0.1%) 0.60% +0.039 pp 0.21% +0.007 pp USD100.10 +25.2% 45 qtrs
31 FMR LLC 9.63M -2.0M (-17.0%) 1.21B -346.5M (-22.3%) 0.55% -0.112 pp 0.06% -0.019 pp USD105.74 +18.5% 70 qtrs
32 DIMENSIONAL FUND ADVISORS LP 9.04M +17.1K (+0.2%) 1.13B -75.8M (-6.3%) 0.52% +0.002 pp 0.24% -0.022 pp USD81.23 +54.2% 51 qtrs
33 GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC 8.48M +306.1K (+3.7%) 1.06B -32.4M (-3.0%) 0.49% +0.018 pp 2.72% -0.372 pp USD103.19 +21.4% 69 qtrs
34 CAPITAL WORLD INVESTORS 8.47M -460.2K (-5.2%) 1.06B -134.9M (-11.3%) 0.48% -0.026 pp 0.14% -0.019 pp USD129.90 -3.5% 6 qtrs
35 AMUNDI 8.19M +1.8M (+28.3%) 1.03B +172.1M (+20.2%) 0.47% +0.104 pp 0.28% +0.004 pp USD114.71 +9.2% 19 qtrs
36 JANUS HENDERSON GROUP PLC 7.45M +952.9K (+14.7%) 933.60M +63.2M (+7.3%) 0.43% +0.055 pp 0.42% +0.021 pp USD97.87 +28.0% 88 qtrs
37 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 7.00M +99.0K (+1.4%) 869.13M -55.0M (-5.9%) 0.40% +0.006 pp 0.59% -0.076 pp USD105.34 +18.9% 58 qtrs
38 FLOSSBACH VON STORCH AG 6.46M -152.3K (-2.3%) 809.08M -76.3M (-8.6%) 0.37% -0.008 pp 3.21% -0.281 pp USD89.50 +40.0% 46 qtrs
39 ROYAL BANK OF CANADA 6.25M +98.8K (+1.6%) 783.62M -40.9M (-5.0%) 0.36% +0.006 pp 0.13% -0.008 pp USD85.44 +46.6% 51 qtrs
40 ENVESTNET ASSET MANAGEMENT INC 5.46M -181.7K (-3.2%) 684.51M -71.6M (-9.5%) 0.31% -0.010 pp 0.20% -0.015 pp USD105.94 +18.3% 51 qtrs
41 RAYMOND JAMES FINANCIAL INC 5.41M -129.6K (-2.3%) 677.85M -63.7M (-8.6%) 0.31% -0.007 pp 0.21% -0.028 pp USD113.52 +10.4% 5 qtrs
42 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 5.21M +1.2M (+29.7%) 652.33M +114.8M (+21.4%) 0.30% +0.069 pp 0.37% +0.051 pp USD98.63 +27.0% 53 qtrs
43 DIAMOND HILL CAPITAL MANAGEMENT INC 5.17M -434.1K (-7.7%) 647.69M -102.9M (-13.7%) 0.30% -0.025 pp 3.32% -0.245 pp USD60.70 +106.4% 85 qtrs
44 SWISS NATIONAL BANK 4.77M -245.9K (-4.9%) 597.56M -74.2M (-11.0%) 0.27% -0.014 pp 0.36% -0.034 pp USD66.92 +87.2% 51 qtrs
45 NEUBERGER BERMAN GROUP LLC 4.76M -481.0K (-9.2%) 595.80M -105.5M (-15.0%) 0.27% -0.027 pp 0.44% -0.069 pp USD121.26 +3.3% 67 qtrs
46 ACADIAN ASSET MANAGEMENT LLC 4.68M +820.6K (+21.3%) 586.55M +69.4M (+13.4%) 0.27% +0.047 pp 0.96% +0.061 pp USD127.74 -1.9% 23 qtrs
47 PNC FINANCIAL SERVICES GROUP, INC. 4.66M +83.4K (+1.8%) 584.33M -29.2M (-4.8%) 0.27% +0.005 pp 0.32% -0.053 pp USD51.63 +142.7% 51 qtrs
48 FIRST TRUST ADVISORS LP 4.54M +669.5K (+17.3%) 569.27M +50.4M (+9.7%) 0.26% +0.039 pp 0.41% +0.027 pp USD129.43 -3.2% 51 qtrs
49 FAYEZ SAROFIM & CO 4.48M -35.4K (-0.8%) 561.36M -47.8M (-7.8%) 0.26% -0.002 pp 1.35% -0.065 pp USD64.32 +94.8% 49 qtrs
50 ALLIANZ ASSET MANAGEMENT GMBH 4.23M +604.3K (+16.7%) 530.45M +44.3M (+9.1%) 0.24% +0.035 pp 0.54% -0.006 pp USD111.34 +12.5% 51 qtrs
51 HSBC HOLDINGS PLC 4.06M +235.3K (+6.1%) 509.45M -3.0M (-0.6%) 0.23% +0.014 pp 0.26% -0.023 pp USD96.63 +29.7% 56 qtrs
52 SUMITOMO MITSUI TRUST HOLDINGS, INC. 4.03M -165.6K (-4.0%) 504.31M -57.0M (-10.2%) 0.23% -0.009 pp 0.30% -0.027 pp USD61.72 +103.0% 59 qtrs
53 NATIONAL PENSION SERVICE 4.02M +457.3K (+12.8%) 504.05M +26.4M (+5.5%) 0.23% +0.026 pp 0.37% +0.002 pp USD87.20 +43.7% 46 qtrs
54 POLEN CAPITAL MANAGEMENT LLC 3.96M -3.5M (-46.6%) 496.43M -497.5M (-50.1%) 0.23% -0.198 pp 2.12% -1.107 pp USD93.42 +34.1% 26 qtrs
55 STIFEL FINANCIAL CORP 3.95M +2.2M (+122.0%) 494.61M +256.4M (+107.6%) 0.23% +0.124 pp 0.44% +0.227 pp USD101.00 +24.0% 48 qtrs
56 CIBC PRIVATE WEALTH GROUP, LLC 3.93M -83.8K (-2.1%) 492.68M -45.2M (-8.4%) 0.23% -0.005 pp 0.83% -0.088 pp USD93.84 +33.5% 48 qtrs
57 PRINCIPAL FINANCIAL GROUP INC 3.61M -315.7K (-8.0%) 452.02M -73.5M (-14.0%) 0.21% -0.018 pp 0.23% -0.034 pp USD61.54 +103.6% 81 qtrs
58 KBC GROUP NV 2.32M +1.3M (+127.3%) 430.43M +293.7M (+214.7%) 0.13% +0.074 pp 0.98% +0.654 pp USD121.58 +3.1% 68 qtrs
59 VONTOBEL HOLDING LTD. 3.38M -1.6M (-32.0%) 424.01M -242.4M (-36.4%) 0.19% -0.091 pp 1.34% -0.677 pp USD106.79 +17.3% 21 qtrs
60 BARCLAYS PLC 3.18M -1.2M (-28.0%) 398.71M -104.9M (-20.8%) 0.18% -0.070 pp 0.10% -0.034 pp USD120.73 +3.8% 51 qtrs
61 WELLCOME TRUST LTD (THE) AS TRUSTEE OF THE WELLCOME TRUST 3.13M +— (+0.0%) 391.53M -27.0M (-6.5%) 0.18% +0.000 pp 4.20% -0.354 pp USD96.06 +30.4% 23 qtrs
62 RATHBONES GROUP PLC 3.12M +107.6K (+3.6%) 390.45M -12.5M (-3.1%) 0.18% +0.006 pp 1.55% -0.091 pp USD102.08 +22.7% 60 qtrs
63 MANUFACTURERS LIFE INSURANCE COMPANY, THE 3.06M +93.5K (+3.2%) 383.13M -13.8M (-3.5%) 0.18% +0.006 pp 0.31% -0.011 pp USD90.36 +38.7% 104 qtrs
64 RHUMBLINE ADVISERS 2.98M -57.5K (-1.9%) 373.23M -33.5M (-8.2%) 0.17% -0.003 pp 0.30% -0.025 pp USD51.21 +144.7% 51 qtrs
65 BNP PARIBAS ARBITRAGE, SNC 2.96M +365.2K (+14.1%) 370.76M +23.3M (+6.7%) 0.17% +0.021 pp 0.17% -0.018 pp USD113.53 +10.4% 51 qtrs
66 BANK OF MONTREAL /CAN/ 2.96M +360.9K (+13.9%) 370.64M +22.8M (+6.5%) 0.17% +0.021 pp 0.13% -0.005 pp USD98.68 +27.0% 51 qtrs
67 US BANCORP \DE\ 2.78M -53.4K (-1.9%) 348.20M -31.2M (-8.2%) 0.16% -0.003 pp 0.41% -0.042 pp USD47.33 +164.7% 51 qtrs
68 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 2.74M -31.0K (-1.1%) 343.64M -27.9M (-7.5%) 0.16% -0.002 pp 0.34% -0.037 pp USD46.53 +169.3% 55 qtrs
69 NINETY ONE UK LTD 2.69M +2.7M (+100.0%) 336.81M +336.8M (+100.0%) 0.15% +0.154 pp 0.72% +0.722 pp USD125.29 +0.0% 1 qtrs NEW
70 BANK JULIUS BAER & CO. LTD, ZURICH 2.55M +1.1M (+77.8%) 319.10M +127.3M (+66.4%) 0.15% +0.064 pp 0.88% +0.340 pp USD120.66 +3.8% 24 qtrs
71 DEKABANK DEUTSCHE GIROZENTRALE 2.54M +— (+0.0%) 298.89M -39.0M (-11.5%) 0.15% +0.000 pp 0.52% -0.052 pp USD97.45 +28.6% 66 qtrs
72 1832 ASSET MANAGEMENT L.P. 2.37M +2.2M (+1,095.7%) 297.40M +270.8M (+1,018.5%) 0.14% +0.125 pp 0.23% +0.206 pp USD124.85 +0.4% 53 qtrs
73 ENSIGN PEAK ADVISORS, INC 2.36M -916.8K (-28.0%) 295.58M -143.2M (-32.6%) 0.14% -0.052 pp 0.52% -0.198 pp USD96.50 +29.8% 25 qtrs
74 AVIVA PLC 2.28M +36.1K (+1.6%) 285.92M -14.9M (-5.0%) 0.13% +0.002 pp 0.48% -0.065 pp USD114.61 +9.3% 51 qtrs
75 LPL FINANCIAL LLC 2.17M +193.2K (+9.8%) 271.74M +7.1M (+2.7%) 0.12% +0.011 pp 0.07% -0.003 pp USD102.51 +22.2% 51 qtrs
76 CI PRIVATE WEALTH, LLC 2.11M +35.5K (+1.7%) 264.32M -13.0M (-4.7%) 0.12% +0.002 pp 0.36% -0.082 pp USD110.56 +13.3% 13 qtrs
77 CITADEL ADVISORS LLC 2.08M +1.5M (+255.1%) 260.61M +182.1M (+232.1%) 0.12% +0.086 pp 0.04% +0.027 pp USD127.73 -1.9% 2 qtrs
78 BAIRD FINANCIAL GROUP, INC. 2.00M -12.2K (-0.6%) 250.08M -18.9M (-7.0%) 0.11% -0.001 pp 0.39% -0.043 pp USD75.62 +65.7% 43 qtrs
79 ABRDN PLC 1.99M +23.8K (+1.2%) 249.77M -12.3M (-4.7%) 0.11% +0.002 pp 0.39% -0.028 pp USD112.84 +11.0% 34 qtrs
80 NEW YORK STATE COMMON RETIREMENT FUND 1.98M -49.7K (-2.4%) 248.41M -23.8M (-8.7%) 0.11% -0.003 pp 0.33% -0.021 pp USD32.33 +287.5% 103 qtrs
81 CANADA PENSION PLAN INVESTMENT BOARD 1.90M +283.6K (+17.6%) 237.71M +21.6M (+10.0%) 0.11% +0.016 pp 0.16% +0.007 pp USD114.42 +9.5% 52 qtrs
82 CITIGROUP INC 1.89M -1.8M (-48.2%) 237.09M -252.5M (-51.6%) 0.11% -0.101 pp 0.10% -0.114 pp USD110.84 +13.0% 108 qtrs
83 CAISSE DE DEPOT ET PLACEMENT DU QUEBEC 1.88M +420.1K (+28.8%) 235.37M +40.0M (+20.5%) 0.11% +0.024 pp 0.40% +0.047 pp USD126.83 -1.2% 51 qtrs
84 JENSEN INVESTMENT MANAGEMENT INC 1.87M -536.4K (-22.3%) 234.68M -88.0M (-27.3%) 0.11% -0.031 pp 3.69% -0.312 pp USD129.89 -3.5% 51 qtrs
85 GREAT WEST LIFE ASSURANCE CO /CAN/ 1.87M -318.6K (-14.5%) 234.67M -56.9M (-19.5%) 0.11% -0.018 pp 0.41% -0.009 pp USD105.93 +18.3% 63 qtrs
86 MARINER, LLC 1.84M -54.4K (-2.9%) 230.41M -23.2M (-9.1%) 0.11% -0.003 pp 0.27% -0.053 pp USD113.31 +10.6% 56 qtrs
87 HIGHTOWER ADVISORS, LLC 1.83M -6.6K (-0.4%) 229.50M -16.7M (-6.8%) 0.10% 0.000 pp 0.25% -0.029 pp USD101.08 +24.0% 67 qtrs
88 B. METZLER SEEL. SOHN & CO. AG 1.81M +52.9K (+3.0%) 226.50M -8.4M (-3.6%) 0.10% +0.003 pp 1.98% -0.096 pp USD123.60 +1.4% 17 qtrs
89 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.74M +603.0K (+53.0%) 218.23M +65.7M (+43.1%) 0.10% +0.035 pp 0.13% +0.032 pp USD128.40 -2.4% 24 qtrs
90 LORD, ABBETT & CO. LLC 1.72M -364.3K (-17.5%) 215.53M -63.7M (-22.8%) 0.10% -0.021 pp 0.66% -0.170 pp USD114.18 +9.7% 38 qtrs
91 ADAGE CAPITAL PARTNERS GP, L.L.C. 1.68M -615.8K (-26.8%) 210.64M -97.0M (-31.5%) 0.10% -0.035 pp 0.32% -0.169 pp USD102.07 +22.7% 64 qtrs
92 TD ASSET MANAGEMENT INC 1.65M -1.4M (-45.5%) 206.80M -199.0M (-49.0%) 0.09% -0.079 pp 0.17% -0.163 pp USD116.81 +7.3% 51 qtrs
93 NATIXIS ADVISORS, L.P. 1.58M -184.7K (-10.4%) 198.54M -38.4M (-16.2%) 0.09% -0.011 pp 0.28% -0.064 pp USD104.48 +19.9% 57 qtrs
94 CERITY PARTNERS LLC 1.58M +49.3K (+3.2%) 197.91M -7.1M (-3.4%) 0.09% +0.003 pp 0.29% -0.044 pp USD116.87 +7.2% 36 qtrs
95 BLAIR WILLIAM & CO/IL 1.58M -20.4K (-1.3%) 197.68M -16.4M (-7.7%) 0.09% -0.001 pp 0.53% -0.039 pp USD75.27 +66.5% 51 qtrs
96 COLONY GROUP, LLC 1.58M +1.0M (+197.0%) 197.57M +126.6M (+178.3%) 0.09% +0.060 pp 0.23% +0.111 pp USD120.73 +3.8% 9 qtrs
97 PROSHARE ADVISORS LLC 1.57M -67.1K (-4.1%) 196.94M -22.6M (-10.3%) 0.09% -0.004 pp 0.35% -0.112 pp USD86.28 +45.2% 77 qtrs
98 LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA 1.65M -23.0K (-1.4%) 178.30M -32.7M (-15.5%) 0.09% -0.001 pp 1.62% -0.235 pp USD31.96 +292.0% 83 qtrs
99 J. STERN & CO. LLP 39.32M +39.0M (+12,439.6%) 39.32M -2.7M (-6.4%) 2.25% +2.233 pp 3.35% +0.173 pp USD125.14 +0.1% 9 qtrs
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
19
Sells
0
Shares acquired
69.2K
Shares disposed
Cash buys
2.00
Cash sales
Net activity
+69,194
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-28 Moreland Mary K Officer I-Discretionary A Common shares without par value 5,314 94.41 501.7K 17,159 I
2026-04-27 STARKS DANIEL J Director P-Purchase A Common shares without par value 10,000 92.65 926.5K 6,751,103 D
2026-04-24 Stratton John G Director A-Award A Common shares without par value 2,286 0.00 21,319 D
2026-04-24 STARKS DANIEL J Director A-Award A Option (right to buy) 7,105 91.86 652.7K 7,105 D
2026-04-24 Roman Michael F Director A-Award A Common shares without par value 2,286 0.00 10,764 D
2026-04-24 O'Grady Michael Director A-Award A Option (right to buy) 5,929 91.86 544.6K 5,929 D
2026-04-24 McKinstry Nancy Director A-Award A Option (right to buy) 2,305 91.86 211.7K 2,305 D
2026-04-24 McDew Darren W Director A-Award A Common shares without par value 2,286 0.00 12,678 D
2026-04-24 Kumbier Michelle Director A-Award A Common shares without par value 2,286 0.00 18,000 D
2026-04-24 Gonzalez Patricia Paola Director A-Award A Common shares without par value 2,286 0.00 9,205 D
2026-04-24 Conroy Kevin T Director Common shares without par value 0 0.00 131,451 D
2026-04-24 Blount Sally E. Director A-Award A Common shares without par value 2,286 0.00 36,344 D
2026-04-24 Babineaux-Fontenot Claire Director A-Award A Common shares without par value 2,286 0.00 7,603 D
2026-04-24 Ahuja Nita Director A-Award A Common shares without par value 2,286 0.00 2,286 D
2026-04-23 Boudreau Philip P Officer I-Discretionary A Common shares without par value 8,909 92.04 820.0K 9,276 I
2026-03-31 Stratton John G Director A-Award A Stock Equivalent Units 382 0.00 13,489 D
2026-03-31 Roman Michael F Director A-Award A Stock Equivalent Units 367 0.00 6,283 D
2026-03-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 321 0.00 5,558 D
2026-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 76 0.00 10,544 D
2026-03-31 Ahuja Nita Director A-Award A Stock Equivalent Units 102 0.00 102 D
2026-03-23 ORVILLE JACOB A Officer Common shares without par value 0 0.00 37,238 D
2026-03-02 Shroff Eric Officer S-Sale D Common shares without par value 709 115.58 81.9K 39,164 D
2026-03-02 Salvadori Daniel Gesua Sive Officer S-Sale D Common shares without par value 885 115.58 102.3K 146,377 D
2026-03-02 Morrone Louis H. Officer S-Sale D Common shares without par value 1,144 115.58 132.2K 76,843 D
2026-03-02 Moreland Mary K Officer S-Sale D Common shares without par value 613 115.58 70.9K 104,291 D
2026-03-02 MCCOY JOHN A. JR. Officer S-Sale D Common shares without par value 585 115.58 67.6K 24,628 D
2026-03-02 Cushman Elizabeth C. Officer S-Sale D Common shares without par value 263 115.58 30.4K 38,573 D
2026-02-27 Shroff Eric Officer F-InKind D Common shares without par value 1,384 116.26 160.9K 39,873 D
2026-02-27 Scoggins Christopher J Officer F-InKind D Common shares without par value 4,997 116.26 581.0K 77,126 D
2026-02-27 Salvadori Daniel Gesua Sive Officer F-InKind D Common shares without par value 6,615 116.26 769.1K 147,262 D
2026-02-27 Morrone Louis H. Officer F-InKind D Common shares without par value 4,040 116.26 469.7K 77,987 D
2026-02-27 Moreland Mary K Officer F-InKind D Common shares without par value 4,630 116.26 538.3K 104,904 D
2026-02-27 MCCOY JOHN A. JR. Officer F-InKind D Common shares without par value 1,142 116.26 132.8K 25,213 D
2026-02-27 Ford Robert B Director / Officer F-InKind D Common shares without par value 30,308 116.26 3.52M 306,461 D
2026-02-27 Earnhardt Lisa D Officer F-InKind D Common shares without par value 8,577 116.26 997.2K 90,407 D
2026-02-27 Cushman Elizabeth C. Officer F-InKind D Common shares without par value 1,421 116.26 165.2K 38,836 D
2026-02-27 Boudreau Philip P Officer F-InKind D Common shares without par value 7,441 116.26 865.1K 71,172 D
2026-02-24 Shroff Eric Officer A-Award A Option (right to buy) 44,821 114.60 5.14M 44,821 D
2026-02-24 Scoggins Christopher J Officer A-Award A Option (right to buy) 76,273 114.60 8.74M 76,273 D
2026-02-24 Salvadori Daniel Gesua Sive Officer A-Award A Common shares without par value 21,644 0.00 153,877 D
2026-02-24 Morrone Louis H. Officer A-Award A Option (right to buy) 63,561 114.60 7.28M 63,561 D
2026-02-24 Moreland Mary K Officer A-Award A Option (right to buy) 57,512 114.60 6.59M 57,512 D
2026-02-24 MCCOY JOHN A. JR. Officer A-Award A Option (right to buy) 22,151 114.60 2.54M 22,151 D
2026-02-24 Ford Robert B Director / Officer A-Award A Option (right to buy) 344,066 114.60 39.43M 344,066 D
2026-02-24 Earnhardt Lisa D Officer A-Award A Common shares without par value 27,056 0.00 98,984 D
2026-02-24 Cushman Elizabeth C. Officer A-Award A Option (right to buy) 61,964 114.60 7.10M 61,964 D
2026-02-24 Boudreau Philip P Officer A-Award A Option (right to buy) 115,413 114.60 13.23M 115,413 D
2026-02-04 STARKS DANIEL J Director P-Purchase A Common shares without par value 5,033 108.33 545.2K 6,738,817 D
2026-01-23 Ford Robert B Director / Officer P-Purchase A Common shares without par value 18,800 107.13 2.01M 216,203 I
2025-12-31 Stratton John G Director A-Award A Stock Equivalent Units 313 0.00 13,034 D
2025-12-31 Roman Michael F Director A-Award A Stock Equivalent Units 301 0.00 5,882 D
2025-12-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 263 0.00 5,208 D
2025-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 62 0.00 10,409 D
2025-12-12 Scoggins Christopher J Officer Option (right to buy) 51,557 75.90 3.91M 0 D
2025-12-12 Ahuja Nita 0 0.00 0
2025-12-11 Salvadori Daniel Gesua Sive Officer G-Gift D Common shares without par value 1,536 123.28 189.4K 132,233 D
2025-11-25 Shroff Eric Officer S-Sale D Common shares without par value 1,586 128.02 203.0K 30,384 D
2025-09-30 Stratton John G Director A-Award A Stock Equivalent Units 293 0.00 12,663 D
2025-09-30 Roman Michael F Director A-Award A Stock Equivalent Units 281 0.00 5,556 D
2025-09-30 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 246 0.00 4,922 D
2025-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 58 0.00 10,300 D
2025-09-01 MCCOY JOHN A. JR. Officer F-InKind D Common shares without par value 79 132.66 10.5K 20,982 D
2025-09-01 Boudreau Philip P Officer F-InKind D Common shares without par value 387 132.66 51.3K 50,616 D
2025-08-08 Boudreau Philip P Officer S-Sale D Common shares without par value 5,550 134.55 746.8K 51,003 D
2025-06-30 Stratton John G Director A-Award A Stock Equivalent Units 282 0.00 12,315 D
2025-06-30 Roman Michael F Director A-Award A Stock Equivalent Units 271 0.00 5,250 D
2025-06-30 Morrone Louis H. Officer F-InKind D Common shares without par value 269 134.38 36.1K 66,609 D
2025-06-30 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 242 0.00 4,655 D
2025-06-30 Alpern Robert J Director A-Award A Stock Equivalent Units 57 0.00 10,195 D
2025-06-27 Cushman Elizabeth C. Officer Option (right to buy) 9,717 116.98 1.14M 0 D
2025-04-30 Blount Sally E. Director S-Sale D Common shares without par value 2,600 129.66 337.1K 34,058 D
2025-04-25 Stratton John G Director A-Award A Common shares without par value 1,635 0.00 19,033 D
2025-04-25 STARKS DANIEL J Director A-Award A Common shares without par value 1,635 0.00 6,728,817 D
2025-04-25 Roman Michael F Director A-Award A Common shares without par value 1,635 0.00 8,478 D
2025-04-25 O'Grady Michael Director A-Award A Common shares without par value 1,635 0.00 5,317 D
2025-04-25 McKinstry Nancy Director A-Award A Common shares without par value 1,635 0.00 38,724 D
2025-04-25 McDew Darren W Director A-Award A Common shares without par value 1,635 0.00 10,392 D
2025-04-25 Kumbier Michelle Director A-Award A Common shares without par value 1,635 0.00 15,714 D
2025-04-25 Gonzalez Patricia Paola Director A-Award A Common shares without par value 1,635 0.00 6,919 D
2025-04-25 Blount Sally E. Director A-Award A Common shares without par value 1,635 0.00 36,658 D
2025-04-25 Babineaux-Fontenot Claire Director A-Award A Common shares without par value 1,635 0.00 5,317 D
2025-04-25 Alpern Robert J Director A-Award A Common shares without par value 1,635 0.00 40,798 D
2025-03-31 Stratton John G Director A-Award A Stock Equivalent Units 277 0.00 11,979 D
2025-03-31 Roman Michael F Director A-Award A Stock Equivalent Units 265 0.00 4,957 D
2025-03-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 248 0.00 4,393 D
2025-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 59 0.00 10,093 D
2025-03-07 Earnhardt Lisa D Officer M-Exempt A Common shares without par value 200 80.98 16.2K 72,128 D
2025-03-06 Earnhardt Lisa D Officer M-Exempt A Common shares without par value 91,167 80.98 7.38M 163,095 D
2025-03-03 Wainer Andrea F Officer S-Sale D Common shares without par value 949 138.17 131.1K 74,381 D
2025-03-03 Shroff Eric Officer S-Sale D Common shares without par value 562 138.17 77.7K 31,970 D
2025-03-03 Morrone Louis H. Officer S-Sale D Common shares without par value 1,111 138.17 153.5K 66,878 D
2025-03-03 Moreland Mary K Officer S-Sale D Common shares without par value 791 138.17 109.3K 95,583 D
2025-03-03 MCCOY JOHN A. JR. Officer S-Sale D Common shares without par value 562 138.17 77.7K 21,061 D
2025-03-01 Shroff Eric Officer Option (right to buy) 13,056 106.24 1.39M 0 D
2025-02-28 Wainer Andrea F Officer F-InKind D Common shares without par value 7,313 135.87 993.6K 75,330 D
2025-02-28 Salvadori Daniel Gesua Sive Officer F-InKind D Common shares without par value 8,462 135.87 1.15M 133,769 D
2025-02-28 Morrone Louis H. Officer F-InKind D Common shares without par value 4,386 135.87 595.9K 67,989 D
2025-02-28 Moreland Mary K Officer F-InKind D Common shares without par value 5,598 135.87 760.6K 96,374 D
2025-02-28 MCCOY JOHN A. JR. Officer F-InKind D Common shares without par value 1,096 135.87 148.9K 21,623 D
2025-02-28 Ford Robert B Director / Officer F-InKind D Common shares without par value 31,651 135.87 4.30M 253,305 D
2025-02-28 Earnhardt Lisa D Officer F-InKind D Common shares without par value 8,322 135.87 1.13M 71,928 D
2025-02-28 Boudreau Philip P Officer F-InKind D Common shares without par value 4,908 135.87 666.8K 56,553 D
2025-02-28 ALLEN HUBERT L Officer F-InKind D Common shares without par value 8,382 135.87 1.14M 191,899 D
2025-02-25 Wainer Andrea F Officer A-Award A Option (right to buy) 45,730 135.42 6.19M 45,730 D
2025-02-25 Salvadori Daniel Gesua Sive Officer A-Award A Common shares without par value 16,534 0.00 142,231 D
2025-02-25 Morrone Louis H. Officer A-Award A Option (right to buy) 38,108 135.42 5.16M 38,108 D
2025-02-25 Moreland Mary K Officer A-Award A Option (right to buy) 39,896 135.42 5.40M 39,896 D
2025-02-25 MCCOY JOHN A. JR. Officer A-Award A Option (right to buy) 15,040 135.42 2.04M 15,040 D
2025-02-25 Ford Robert B Director / Officer A-Award A Common shares without par value 64,897 0.00 284,956 D
2025-02-25 Earnhardt Lisa D Officer A-Award A Common shares without par value 18,788 0.00 80,250 D
2025-02-25 Boudreau Philip P Officer A-Award A Option (right to buy) 83,783 135.42 11.35M 83,783 D
2025-02-25 ALLEN HUBERT L Officer A-Award A Common shares without par value 15,475 0.00 200,281 D
2025-02-18 Shroff Eric Officer Option (right to buy) 20,404 117.58 2.40M 0 D
2025-02-05 Ford Robert B Director / Officer M-Exempt D Option (right to buy) 285,388 38.40 10.96M 0 D
2025-01-30 Salvadori Daniel Gesua Sive Officer M-Exempt D Option (right to buy) 23,771 38.40 912.8K 0 D
2025-01-30 ALLEN HUBERT L Officer M-Exempt D Option (right to buy) 58,428 38.40 2.24M 0 D
2025-01-29 ALLEN HUBERT L Officer S-Sale D Common shares without par value 131,360 128.35 16.86M 184,806 D
2025-01-28 Morrone Louis H. Officer S-Sale D Common shares without par value 2,644 127.39 336.8K 0 I
2024-12-31 Stratton John G Director A-Award A Stock Equivalent Units 324 0.00 11,650 D
2024-12-31 Roman Michael F Director A-Award A Stock Equivalent Units 311 0.00 4,670 D
2024-12-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 291 0.00 4,125 D
2024-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 69 0.00 9,988 D
2024-10-21 ALLEN HUBERT L Officer M-Exempt A Common shares without par value 157,421 47.00 7.40M 342,227 D
2024-09-30 Stratton John G Director A-Award A Stock Equivalent Units 322 0.00 11,271 D
2024-09-30 Roman Michael F Director A-Award A Stock Equivalent Units 309 0.00 4,338 D
2024-09-30 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 289 0.00 3,815 D
2024-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 69 0.00 9,872 D
2024-09-12 Ford Robert B Director / Officer M-Exempt A Common shares without par value 14,243 48.90 696.5K 361,738
2024-09-04 MCCOY JOHN A. JR. Officer S-Sale D Common shares without par value 27 114.83 3.1K 18,681
2024-09-01 MCCOY JOHN A. JR. Officer F-InKind D Common shares without par value 52 113.27 5.9K 18,708
2024-09-01 Boudreau Philip P Officer F-InKind D Common shares without par value 387 113.27 43.8K 38,966
2024-07-01 Morrone Louis H. Officer F-InKind D Common shares without par value 556 103.91 57.8K 62,143
2024-06-30 Stratton John G Director A-Award A Stock Equivalent Units 353 0.00 10,895
2024-06-30 Roman Michael F Director A-Award A Stock Equivalent Units 339 0.00 4,009
2024-06-30 Morrone Louis H. Officer F-InKind D Common shares without par value 269 103.91 28.0K 62,699
2024-06-30 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 317 0.00 3,509
2024-06-30 Alpern Robert J Director A-Award A Stock Equivalent Units 75 0.00 9,754
2024-05-10 Funck, Jr. Robert E. Officer M-Exempt D Option (right to buy) 10,097 47.00 474.6K 45,000
2024-05-07 Earnhardt Lisa D Officer S-Sale D Common shares without par value 22,852 106.25 2.43M 61,462
2024-04-26 Stratton John G Director A-Award A Common shares without par value 1,866 0.00 17,398
2024-04-26 STARKS DANIEL J Director A-Award A Option (right to buy) 5,277 107.14 565.4K 5,277
2024-04-26 Roman Michael F Director A-Award A Common shares without par value 1,866 0.00 6,843
2024-04-26 O'Grady Michael Director A-Award A Option (right to buy) 4,404 107.14 471.8K 4,404
2024-04-26 McKinstry Nancy Director A-Award A Option (right to buy) 6,850 107.14 733.9K 6,850
2024-04-26 McDew Darren W Director A-Award A Common shares without par value 1,866 0.00 8,757
2024-04-26 Kumbier Michelle Director A-Award A Common shares without par value 1,866 0.00 14,079
2024-04-26 Gonzalez Patricia Paola Director A-Award A Common shares without par value 1,866 0.00 5,284
2024-04-26 Blount Sally E. Director A-Award A Common shares without par value 1,866 0.00 35,023
2024-04-26 Babineaux-Fontenot Claire Director A-Award A Common shares without par value 1,866 0.00 3,682
2024-04-26 Alpern Robert J Director A-Award A Common shares without par value 1,866 0.00 39,163
2024-03-31 Stratton John G Director A-Award A Stock Equivalent Units 323 0.00 10,486
2024-03-31 Roman Michael F Director A-Award A Stock Equivalent Units 310 0.00 3,650
2024-03-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 290 0.00 3,174
2024-03-31 Alpern Robert J Director A-Award A Stock Equivalent Units 69 0.00 9,628
2024-03-01 Salvadori Daniel Gesua Sive Officer S-Sale D Common shares without par value 963 118.50 114.1K 125,697
2024-03-01 Morrone Louis H. Officer S-Sale D Common shares without par value 801 118.50 94.9K 62,968
2024-03-01 Moreland Mary K Officer S-Sale D Common shares without par value 676 118.50 80.1K 91,260
2024-03-01 MCCOY JOHN A. JR. Officer S-Sale D Common shares without par value 472 118.50 55.9K 18,760
2024-03-01 Earnhardt Lisa D Officer S-Sale D Common shares without par value 694 118.50 82.2K 84,314
2024-03-01 ALLEN HUBERT L Officer S-Sale D Common shares without par value 853 118.50 101.1K 184,806
2024-02-29 Wainer Andrea F Officer F-InKind D Common shares without par value 8,339 120.05 1.00M 70,365
2024-02-29 Salvadori Daniel Gesua Sive Officer F-InKind D Common shares without par value 8,874 120.05 1.07M 126,660
2024-02-29 Morrone Louis H. Officer F-InKind D Common shares without par value 3,455 120.05 414.8K 63,769
2024-02-29 Moreland Mary K Officer F-InKind D Common shares without par value 5,862 120.05 703.7K 91,936
2024-02-29 MCCOY JOHN A. JR. Officer F-InKind D Common shares without par value 921 120.05 110.6K 19,232
2024-02-29 Funck, Jr. Robert E. Officer F-InKind D Common shares without par value 11,415 120.05 1.37M 211,341
2024-02-29 Ford Robert B Director / Officer F-InKind D Common shares without par value 31,610 120.05 3.79M 220,059
2024-02-29 Earnhardt Lisa D Officer F-InKind D Common shares without par value 7,669 120.05 920.7K 85,008
2024-02-29 Boudreau Philip P Officer F-InKind D Common shares without par value 1,738 120.05 208.6K 39,353
2024-02-29 ALLEN HUBERT L Officer F-InKind D Common shares without par value 8,214 120.05 986.1K 185,659
2024-02-23 Wainer Andrea F Officer M-Exempt A Common shares without par value 12,500 59.94 749.3K 91,204
2024-02-21 Wainer Andrea F Officer A-Award A Option (right to buy) 51,397 116.98 6.01M 51,397
2024-02-21 Salvadori Daniel Gesua Sive Officer A-Award A Option (right to buy) 58,898 116.98 6.89M 58,898
2024-02-21 Morrone Louis H. Officer A-Award A Option (right to buy) 46,257 116.98 5.41M 46,257
2024-02-21 Moreland Mary K Officer A-Award A Option (right to buy) 39,734 116.98 4.65M 39,734
2024-02-21 MCCOY JOHN A. JR. Officer A-Award A Common shares without par value 4,407 0.00 20,153
2024-02-21 Funck, Jr. Robert E. Officer A-Award A Option (right to buy) 92,137 116.98 10.78M 92,137
2024-02-21 Ford Robert B Director / Officer A-Award A Common shares without par value 70,332 0.00 251,669
2024-02-21 Earnhardt Lisa D Officer A-Award A Option (right to buy) 64,787 116.98 7.58M 64,787
2024-02-21 Boudreau Philip P Officer A-Award A Option (right to buy) 86,519 116.98 10.12M 86,519
2024-02-21 ALLEN HUBERT L Officer A-Award A Common shares without par value 17,914 0.00 193,873
2024-02-19 Shroff Eric Officer Option (right to buy) 20,045 124.04 2.49M 0 D
2024-02-17 MCCOY JOHN A. JR. Officer D Option (right to buy) 12,759 106.24 1.36M 0
2024-01-29 Wainer Andrea F Officer M-Exempt A Common shares without par value 25,000 44.40 1.11M 90,027
2023-12-31 Stratton John G Director A-Award A Stock Equivalent Units 333 0.00 10,114
2023-12-31 Roman Michael F Director A-Award A Stock Equivalent Units 320 0.00 3,324
2023-12-31 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 299 0.00 2,870
2023-12-31 Alpern Robert J Director A-Award A Stock Equivalent Units 71 0.00 9,512
2023-12-14 Wainer Andrea F Officer S-Sale D Common shares without par value 15,000 108.00 1.62M 65,027
2023-10-26 STARKS DANIEL J Director S-Sale D Common shares without par value 26,907 93.81 2.52M 6,748,409
2023-09-30 Stratton John G Director A-Award A Stock Equivalent Units 379 0.00 9,729
2023-09-30 Roman Michael F Director A-Award A Stock Equivalent Units 363 0.00 2,988
2023-09-30 Gonzalez Patricia Paola Director A-Award A Stock Equivalent Units 340 0.00 2,557
2023-09-30 Alpern Robert J Director A-Award A Stock Equivalent Units 81 0.00 9,392
2023-09-13 Funck, Jr. Robert E. Officer G-Gift D Common shares without par value 20,000 0.00 198,237
2023-09-01 MCCOY JOHN A. JR. Officer A-Award A Common shares without par value 531 0.00 15,746
2023-09-01 Boudreau Philip P Officer A-Award A Common shares without par value 2,620 0.00 18,067
2023-08-08 Wainer Andrea F Officer S-Sale D Common shares without par value 272 105.43 28.7K 65,043
2023-07-27 STARKS DANIEL J Director S-Sale D Common shares without par value 20,934 113.43 2.37M 6,804,382
2023-07-01 Morrone Louis H. Officer F-InKind D Common shares without par value 556 109.02 60.6K 54,915

Executive team

Top executives
EBIT / Employee
77.3K
Shares Outstanding
1.74B

Executive compensation

Executive compensation (annual)
# Year Executive Salary Bonus Stock award Option award Incentive Other Total % Stock-
based
Filing
1 2025 Robert B. Ford , Chairman of the Board and Chief Executive Officer 1.50M 8.79M 8.79M 1.97M 3.15M 24.20M 72.63%
2 2025 Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer 974.2K 3.05M 3.05M 1.06M 968.7K 9.09M 67.02%
3 2025 Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices 924.2K 2.54M 2.54M 1.28M 773.7K 8.07M 63.05%
4 2025 Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary 524.0K 2.10M 2.10M 447.5K 1.83M 7.00M 59.91%
5 2025 Christopher J. Scoggins , Executive Vice President, Diabetes Care 859.5K 1.66M 1.66M 1.10M 1.32M 6.60M 50.37%
6 2025 Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 924.2K 2.24M 2.24M 388.2K 744.0K 6.53M 68.53%
7 2024 Robert B. Ford , Chairman of the Board and Chief Executive Officer 1.50M 8.23M 8.23M 2.86M 1.96M 22.78M 72.24%
8 2024 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.50M 8.23M 8.23M 2.86M 1.96M 22.78M 72.24%
9 2024 Robert E. Funck, Jr. Former Executive Vice President, Finance 535.1K 2.87M 2.87M 564.0K 1.42M 8.26M 69.46%
10 2024 Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer 884.0K 2.69M 2.69M 1.22M 730.6K 8.23M 65.48%
11 2024 Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer 884.0K 2.69M 2.69M 1.22M 730.6K 8.23M 65.48%
12 2024 Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary 911.2K 2.10M 2.10M 1.09M 1.78M 7.98M 52.51%
13 2024 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 911.2K 2.10M 2.10M 1.09M 1.78M 7.98M 52.51%
14 2024 Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices 879.3K 2.02M 2.02M 1.25M 396.6K 6.56M 61.50%
15 2024 Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices 879.3K 2.02M 2.02M 1.25M 396.6K 6.56M 61.50%
16 2024 Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 879.3K 1.83M 1.83M 855.4K 388.4K 5.79M 63.33%
17 2024 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 879.3K 1.83M 1.83M 855.4K 388.4K 5.79M 63.33%
18 2023 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.50M 7.44M 7.44M 2.95M 3.95M 23.27M 63.93%
19 2023 Robert B. Ford , Chairman of the Board and Chief Executive Officer 1.50M 7.44M 7.44M 2.95M 3.95M 23.27M 63.93%
20 2023 Robert E. Funck, Jr., Executive Vice President, Finance 875.0K 2.59M 2.59M 1.06M 1.87M 8.99M 57.70%
21 2023 Robert E. Funck, Jr. Former Executive Vice President, Finance 875.0K 2.59M 2.59M 1.06M 1.87M 8.99M 57.70%
22 2023 Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary 830.0K 1.96M 1.96M 941.7K 1.73M 7.42M 52.82%
23 2023 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 830.0K 1.96M 1.96M 941.7K 1.73M 7.42M 52.82%
24 2023 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 790.0K 1.88M 1.88M 880.3K 503.9K 5.93M 63.37%
25 2023 Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 790.0K 1.88M 1.88M 880.3K 503.9K 5.93M 63.37%
26 2023 Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices 737.7K 1.68M 1.68M 904.9K 487.2K 5.50M 61.27%
27 2023 Lisa D. Earnhardt, Executive Vice President and Group President, Medical Devices 737.7K 1.68M 1.68M 904.9K 487.2K 5.50M 61.27%
28 2023 Philip P. Boudreau, Senior Vice President, Finance and Chief Financial Officer 513.9K 786.0K 786.3K 583.5K 647.4K 3.32M 47.40%
29 2023 Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer 513.9K 786.0K 786.3K 583.5K 647.4K 3.32M 47.40%
30 2023 Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer 513.9K 786.0K 786.3K 583.5K 647.4K 3.32M 47.40%
31 2022 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.50M 8.70M 8.70M 2.23M 591.3K 21.72M 80.10%
32 2022 Robert E. Funck, Jr., Executive Vice President, Finance 866.2K 3.37M 3.37M 956.0K 578.3K 9.15M 73.75%
33 2022 Robert E. Funck, Jr. Former Executive Vice President, Finance 866.2K 3.37M 3.37M 956.0K 578.3K 9.15M 73.75%
34 2022 Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer 866.2K 3.37M 3.37M 956.0K 578.3K 9.15M 73.75%
35 2022 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 790.0K 2.81M 2.81M 600.5K 142.4K 7.16M 78.58%
36 2022 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 817.6K 2.40M 2.40M 871.5K 536.9K 7.02M 68.29%
37 2022 Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics 710.0K 2.23M 2.23M 906.3K 209.4K 6.29M 70.96%
38 2021 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.48M 8.69M 8.69M 3.17M 2.88M 24.91M 69.75%
39 2021 Miles D. White, Former Executive Chairman of the Board 1.90M 5.50M 5.50M 3.05M 15.95M 68.95%
40 2021 Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer 825.0K 3.00M 3.00M 1.05M 1.67M 9.54M 62.89%
41 2021 Robert E. Funck, Jr., Executive Vice President, Finance 825.0K 3.00M 3.00M 1.05M 1.67M 9.54M 62.89%
42 2021 Andrea F. Wainer, Executive Vice President, Rapid and Molecular Diagnostics 699.6K 2.39M 2.39M 931.6K 842.0K 7.25M 65.89%
43 2021 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 760.0K 2.12M 2.12M 921.7K 941.1K 6.85M 61.73%
44 2021 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 715.5K 2.39M 2.39M 925.7K 323.9K 6.74M 70.85%
45 2020 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.30M 5.62M 5.62M 3.68M 4.23M 20.45M 55.01%
46 2020 Robert B. Ford, President and Chief Executive Officer, and Director 1.30M 5.62M 5.62M 3.68M 77.9K 20.45M 55.01%
47 2020 Miles D. White, Former Executive Chairman of the Board 1.90M 6.00M 6.00M 1.25M 4.68M 19.83M 60.51%
48 2020 Miles D. White, Executive Chairman of the Board 1.90M 6.00M 6.00M 1.25M 1.26M 19.83M 60.51%
49 2020 Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer 813.5K 2.22M 2.22M 1.28M 3.27M 9.80M 45.22%
50 2020 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 751.3K 1.87M 1.87M 917.7K 3.06M 8.48M 44.23%
51 2020 John F. Ginascol, Executive Vice President, Core Diagnostics 708.3K 1.65M 1.65M 857.3K 112.7K 6.77M 48.88%
52 2020 Daniel G. Salvadori, Executive Vice President, Nutritional Products 710.0K 1.90M 1.90M 905.5K 79.4K 5.98M 63.65%
53 2020 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 710.0K 1.90M 1.90M 905.5K 556.4K 5.98M 63.65%
54 2020 Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer 207.8K 1.23M 1.23M 38.3K 3.49M 70.56%
55 2019 Miles D. White, Former Executive Chairman of the Board 1.90M 7.56M 7.56M 4.41M 6.37M 27.80M 54.40%
56 2019 Miles D. White, Executive Chairman of the Board 1.90M 7.56M 7.56M 4.41M 664.4K 27.80M 54.40%
57 2019 Miles D. White, Chairman of the Board, Chief Executive Officer, and Director 1.90M 7.56M 7.56M 4.41M 664.4K 27.80M 54.40%
58 2019 Robert B. Ford, President and Chief Executive Officer, and Director 1.00M 3.48M 3.48M 1.56M 71.8K 11.90M 58.43%
59 2019 Robert B. Ford, President and Chief Operating Officer, and Director 1.00M 3.48M 3.48M 1.56M 71.8K 11.90M 58.43%
60 2019 Robert B. Ford, Chairman of the Board and Chief Executive Officer 1.00M 3.48M 3.48M 1.56M 2.38M 11.90M 58.43%
61 2019 Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer 825.0K 2.45M 2.45M 1.11M 71.3K 9.02M 54.35%
62 2019 Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer 825.0K 2.45M 2.45M 1.11M 71.3K 9.02M 54.35%
63 2019 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 710.0K 2.20M 2.20M 879.7K 1.50M 7.49M 58.78%
64 2019 Lisa D. Earnhardt, Executive Vice President, Medical Devices 400.1K 4.61M 1.35M 910.4K 19.8K 7.48M 79.75%
65 2019 Daniel G. Salvadori, Executive Vice President, Nutritional Products 704.9K 2.35M 2.35M 903.4K 59.8K 6.77M 69.51%
66 2019 Daniel G. Salvadori, Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products 704.9K 2.35M 2.35M 903.4K 455.5K 6.77M 69.51%
67 2018 Miles D. White, Executive Chairman of the Board 1.90M 7.50M 7.50M 4.78M 1.19M 24.25M 61.84%
68 2018 Miles D. White, Chairman of the Board, Chief Executive Officer, and Director 1.90M 7.50M 7.50M 4.78M 1.19M 24.25M 61.84%
69 2018 Robert B. Ford, President and Chief Operating Officer 784.3K 2.69M 2.69M 1.30M 279.2K 8.13M 66.24%
70 2018 Robert B. Ford, President and Chief Executive Officer, and Director 784.3K 2.69M 2.69M 1.30M 279.2K 8.13M 66.24%
71 2018 Robert B. Ford, President and Chief Operating Officer, and Director 784.3K 2.69M 2.69M 1.30M 279.2K 8.13M 66.24%
72 2018 Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer 796.1K 2.69M 2.69M 974.6K 73.5K 7.61M 70.72%
73 2018 Brian B. Yoor, Former Executive Vice President, Finance and Chief Financial Officer 796.1K 2.69M 2.69M 974.6K 73.5K 7.61M 70.72%
74 2018 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 706.7K 2.69M 2.69M 902.0K 120.3K 7.32M 73.57%
75 2018 Stephen R. Fussell, Executive Vice President, Human Resources 620.0K 2.69M 2.69M 682.0K 97.8K 6.84M 78.72%
76 2018 Daniel G. Salvadori, Executive Vice President, Nutritional Products 675.0K 1.99M 1.99M 803.2K 434.5K 5.95M 66.97%
77 2017 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 4.10M 4.10M 4.50M 4.37M 18.97M 43.22%
78 2017 Miles D. White, Chairman of the Board, Chief Executive Officer, and Director 1.90M 4.10M 4.10M 4.50M 1.02M 18.97M 43.22%
79 2017 Michael T. Rousseau , President, Cardiovascular and Neuromodulation 644.2K 5.00M 643.8K 12.52M 18.81M 0.00%
80 2017 Eric S. Fain , Senior Vice President, Group President, Cardiovascular and Neuromodulation 557.0K 3.02M 1.02M 174.7K 8.55M 13.33M 30.38%
81 2017 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 690.1K 1.07M 1.07M 1.02M 71.1K 4.87M 44.06%
82 2017 Robert B. Ford, Executive Vice President, Medical Devices 675.0K 974.9K 975.0K 1.07M 1.01M 4.70M 41.47%
83 2017 Robert B. Ford, President and Chief Operating Officer, and Director 675.0K 974.9K 975.0K 1.07M 60.9K 4.70M 41.47%
84 2017 Robert B. Ford, President and Chief Operating Officer 675.0K 974.9K 975.0K 1.07M 60.9K 4.70M 41.47%
85 2017 Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer 643.3K 877.4K 877.5K 1.06M 63.0K 4.54M 38.68%
86 2017 Daniel G. Salvadori, Executive Vice President, Nutritional Products 608.5K 1.25M 1.26M 733.7K 54.6K 4.09M 61.45%
87 2016 Miles D. White, Chairman of the Board, Chief Executive Officer, and Director 1.90M 5.25M 5.25M 3.20M 825.6K 20.29M 51.76%
88 2016 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 5.25M 5.25M 3.20M 4.69M 20.29M 51.76%
89 2016 Thomas C. Freyman , Executive Vice President, Finance and Administration 999.4K 2.12M 2.12M 1.35M 404.9K 7.00M 60.70%
90 2016 Michael J. Warmuth, Executive Vice President, Established 691.9K 1.37M 1.37M 730.0K 1.19M 5.36M 51.31%
91 2016 Brian J. Blaser, Executive Vice President, Diagnostic Products 692.1K 1.56M 1.56M 664.3K 621.5K 5.10M 61.24%
92 2016 Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer 584.2K 934.8K 935.0K 622.8K 60.2K 3.59M 52.08%
93 2015 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 6.25M 6.25M 3.30M 1.70M 19.40M 64.42%
94 2015 Thomas C. Freyman , Executive Vice President, Finance and Administration 975.1K 1.90M 1.90M 1.02M 274.2K 6.07M 62.62%
95 2015 Thomas C. Freyman, Executive Vice President, Finance and Administration 975.1K 1.90M 1.90M 1.02M 274.2K 6.07M 62.62%
96 2015 Michael J. Warmuth, Executive Vice President, Established 675.0K 1.21M 1.21M 700.0K 981.7K 4.77M 50.61%
97 2015 Brian J. Blaser, Executive Vice President, Diagnostic Products 675.0K 1.15M 1.15M 700.0K 305.4K 3.99M 57.89%
98 2015 John M. Capek, Executive Vice President, Ventures 675.0K 1.10M 1.10M 585.0K 301.3K 3.77M 58.54%
99 2015 Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer 437.9K 841.8K 833.1K 427.5K 172.4K 2.71M 61.74%
100 2015 Brian B. Yoor, Executive Vice President, Finance and Chief Financial Officer 437.9K 841.8K 833.1K 427.5K 172.4K 2.71M 61.74%
101 2014 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.97M 4.65M 4.65M 3.80M 2.66M 17.73M 52.45%
102 2014 Thomas C. Freyman , Executive Vice President, Finance and Administration 1.01M 1.28M 1.28M 1.20M 2.53M 7.31M 35.06%
103 2014 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 1.01M 1.28M 1.28M 1.20M 2.53M 7.31M 35.06%
104 2014 Thomas C. Freyman, Executive Vice President, Finance and Administration 1.01M 1.28M 1.28M 1.20M 2.53M 7.31M 35.06%
105 2014 John C. Landgraf, Executive Vice President, Nutrition Products 743.3K 990.1K 990.2K 401.6K 1.53M 4.66M 42.53%
106 2014 Brian J. Blaser, Executive Vice President, Diagnostic Products 690.0K 1.12M 1.12M 668.0K 653.7K 4.25M 52.67%
107 2014 John M. Capek, Executive Vice President, Ventures 696.8K 904.0K 904.0K 653.8K 640.7K 3.80M 47.59%
108 2014 John M. Capek, Executive Vice President, Medical Devices 696.8K 904.0K 904.0K 653.8K 640.7K 3.80M 47.59%
109 2013 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 7.34M 7.06M 3.15M 1.42M 20.87M 69.01%
110 2013 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 969.7K 2.01M 1.78M 912.0K 206.6K 5.88M 64.49%
111 2013 Thomas C. Freyman, Executive Vice President, Finance and Administration 969.7K 2.01M 1.78M 912.0K 206.6K 5.88M 64.49%
112 2013 Hubert L. Allen, Executive Vice President, General Counsel and Secretary 650.0K 1.11M 952.1K 682.5K 380.7K 3.77M 54.59%
113 2013 Richard W. Ashley, Executive Vice President, Corporate Development 629.5K 2.22M 590.0K 205.9K 3.64M 60.85%
114 2013 Brian J. Blaser, Executive Vice President, Diagnostic Products 614.6K 1.11M 952.1K 800.0K 105.3K 3.58M 57.54%
115 2013 Brian J. Blaser, Executive Vice President, Diagnostics Products 614.6K 1.11M 952.1K 800.0K 105.3K 3.58M 57.54%
116 2012 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 9.43M 2.06M 4.70M 7.03M 25.12M 45.73%
117 2012 Laura J. Schumacher Executive Vice President, General Counsel and Secretary 831.7K 1.10M 4.49M 576.8K 1.27M 1.93M 10.19M 49.68%
118 2012 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 946.7K 1.20M 3.34M 729.6K 1.27M 2.18M 9.66M 42.13%
119 2012 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 863.9K 3.34M 729.6K 2.50M 513.8K 7.95M 51.22%
120 2012 Carlos Alban Senior Vice President, Proprietary Pharmaceuticals, Global Commercial Operations 615.8K 300.0K 2.70M 331.5K 675.0K 1.91M 6.53M 46.46%
121 2011 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.90M 9.76M 1.84M 4.20M 6.32M 24.01M 48.29%
122 2011 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 946.7K 2.86M 537.6K 1.27M 2.34M 7.95M 42.70%
123 2011 Laura J. Schumacher Executive Vice President, General Counsel and Secretary 827.5K 1.91M 358.2K 1.18M 1.30M 5.57M 40.66%
124 2011 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 825.0K 1.83M 343.3K 1.23M 1.33M 5.55M 39.07%
125 2011 Edward L. Michael Executive Vice President, Diagnostic Products 634.4K 1.83M 499.4K 750.0K 1.62M 5.33M 43.67%
126 2010 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.89M 10.90M 2.73M 3.70M 6.35M 25.56M 53.29%
127 2010 James V. Mazzo, Senior Vice President, Abbott Medical Optics 814.6K 2.21M 265.2K 398.4K 7.81M 11.51M 21.53%
128 2010 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 941.9K 4.98M 804.8K 1.20M 1.64M 9.57M 60.46%
129 2010 Richard A. Gonzalez Executive Vice President, Pharmaceutical Products Group 742.1K 300.0K 5.14M 848.9K 574.3K 7.60M 67.56%
130 2010 Laura J. Schumacher Executive Vice President, General Counsel and Secretary 823.3K 3.90M 535.9K 1.10M 766.8K 7.13M 62.26%
131 2009 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.85M 12.45M 3.02M 3.90M 5.00M 26.21M 59.00%
132 2009 James V. Mazzo, Senior Vice President, Abbott Medical Optics 640.9K 2.62M 349.0K 6.79M 10.39M 25.17%
133 2009 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 914.5K 4.12M 1.00M 1.29M 2.23M 9.56M 53.64%
134 2009 Laura J. Schumacher Executive Vice President, General Counsel and Secretary 799.4K 2.48M 602.3K 1.08M 768.3K 5.72M 53.83%
135 2009 Laura J. Schumacher, Executive Vice President, General Counsel and Secretary 799.4K 2.48M 602.3K 1.08M 768.3K 5.72M 53.83%
136 2009 Olivier Bohuon, Executive Vice President, Abbott Pharmaceutical Products Group 772.4K 2.39M 572.5K 730.0K 767.7K 5.23M 56.62%
137 2008 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.80M 7.50M 10.76M 4.20M 4.00M 28.25M 64.62%
138 2008 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 886.4K 1.74M 1.46M 1.23M 1.15M 6.47M 49.48%
139 2008 James L. Tyree, Executive Vice President, Pharmaceutical Products 697.3K 2.24M 1.67M 792.6K 835.9K 6.23M 62.68%
140 2008 John M. Capek, Executive Vice President, Medical Devices 679.4K 1.73M 1.14M 678.2K 1.12M 5.34M 53.64%
141 2008 Laura J. Schumacher Executive Vice President, General Counsel and Secretary 774.8K 1.51M 1.50M 986.7K 487.5K 5.26M 57.20%
142 2008 Laura J. Schumacher, Executive Vice President, General Counsel and Secretary 774.8K 1.51M 1.50M 986.7K 487.5K 5.26M 57.20%
143 2007 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.73M 7.36M 14.77M 4.05M 4.05M 31.95M 69.25%
144 2007 Richard A. Gonzalez, Former Chief Operating Officer and Director 951.8K 7.64M 5.91M 1.29M 1.37M 17.15M 78.96%
145 2007 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 852.5K 2.55M 3.53M 1.20M 1.19M 9.33M 65.20%
146 2007 William G. Dempsey, Former Executive Vice President, Pharmaceutical Products Group 594.8K 2.29M 2.90M 852.3K 1.12M 7.76M 66.94%
147 2007 Holger A. Liepmann, Executive Vice President, Global Nutrition 671.7K 1.96M 1.81M 548.0K 1.20M 6.19M 60.91%
148 2007 James L. Tyree, Executive Vice President, Pharmaceutical Products Group 634.3K 1.98M 1.76M 713.7K 664.9K 5.75M 65.02%
149 2007 James L. Tyree, Executive Vice President, Pharmaceutical Products 634.3K 1.98M 1.76M 713.7K 664.9K 5.75M 65.02%
150 2007 Stephen R. Fussell, Senior Vice President, Human Resources 454.7K 2.12M 2.23M 480.0K 464.7K 5.75M 75.66%
151 2006 Miles D. White, Chairman of the Board, Chief Executive Officer and Director 1.66M 10.56M 8.48M 4.05M 2.16M 26.92M 70.74%
152 2006 Richard A. Gonzalez, Chief Operating Officer and Director 973.9K 8.50M 4.32M 1.54M 1.39M 16.71M 76.70%
153 2006 Richard A. Gonzalez, Former Chief Operating Officer and Director 973.9K 8.50M 4.32M 1.54M 1.39M 16.71M 76.70%
154 2006 Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer 812.9K 1.83M 1.27M 1.09M 1.02M 6.02M 51.46%
155 2006 Holger Liepmann, Executive Vice President, Global Nutrition 626.0K 1.69M 1.33M 657.0K 1.38M 5.69M 53.10%
156 2006 Holger A. Liepmann, Executive Vice President, Global Nutrition 626.0K 1.69M 1.33M 657.0K 1.38M 5.69M 53.10%
157 2006 William G. Dempsey, Former Executive Vice President, Pharmaceutical Products Group 630.6K 1.77M 1.28M 756.0K 1.03M 5.47M 55.84%
158 2006 William G. Dempsey, Executive Vice President, Pharmaceutical Products Group 630.6K 1.77M 1.28M 756.0K 1.03M 5.47M 55.84%
159 2006 Jeffrey M. Leiden, Former President and Chief Operating Officer, Pharmaceutical Products Group and Director 225.1K 4.05M 485.8K 4.76M 85.08%
160 2005 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.61M 2.65M 2.96M 440.8K 519.7K 8.18M 41.59%
161 2005 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 905.9K 1.00M 2.15M 675.7K 364.7K 5.10M 55.47%
162 2005 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 905.9K 1.05M 2.15M 287.3K 219.5K 4.62M 52.87%
163 2005 William G. Dempsey Senior Vice President, Pharmaceutical Operations 591.9K 613.0K 431.5K 478.8K 280.7K 2.40M 37.99%
164 2005 Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer 730.3K 825.0K 431.5K 313.2K 55.6K 2.36M 31.62%
165 2004 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.55M 2.70M 2.40M 224.1K 165.4K 7.04M 37.28%
166 2004 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 875.4K 1.10M 1.75M 313.2K 108.5K 4.14M 49.71%
167 2004 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 875.4K 1.10M 1.75M 26.1K 97.1K 3.85M 46.10%
168 2004 Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer 617.3K 685.0K 349.3K 41.5K 39.2K 1.73M 22.56%
169 2004 William G. Dempsey Senior Vice President, Pharmaceutical Operations 565.8K 567.5K 349.3K 25.3K 112.9K 1.62M 23.11%
170 2003 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.56M 1.75M 404.3K 162.4K 3.88M 10.42%
171 2003 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 882.7K 885.0K 478.8K 95.0K 2.34M 20.45%
172 2003 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 882.7K 970.0K 19.9K 114.7K 1.99M 1.00%
173 2003 Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer 585.6K 589.0K 287.3K 37.3K 1.50M 19.16%
174 2003 William G. Dempsey Senior Vice President, Pharmaceutical Operations 534.8K 540.5K 63.8K 100.5K 1.24M 5.15%
175 2002 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.50M 1.25M 11.47M 675.7K 140.9K 15.03M 80.79%
176 2002 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 807.4K 680.0K 8.31M 478.8K 106.2K 10.39M 84.66%
177 2002 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 802.5K 505.0K 8.31M 478.8K 80.9K 10.18M 86.36%
178 2002 William G. Dempsey Senior Vice President, International Operations 501.6K 375.0K 1.43M 250.0K 104.5K 2.66M 63.18%
179 2002 William G. Dempsey Senior Vice President, Pharmaceutical Operations 501.6K 375.0K 1.43M 106.4K 104.5K 2.52M 61.08%
180 2002 Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer 493.3K 375.0K 1.43M 55.4K 35.9K 2.39M 62.21%
181 2002 Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer 493.3K 375.0K 1.43M 26.6K 35.9K 2.36M 61.75%
182 2001 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.45M 2.10M 2.09M 525.0K 173.0K 6.33M 41.28%
183 2001 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 619.6K 700.0K 450.0K 25.0K 1.79M 25.08%
184 2001 Thomas C. Freyman Executive Vice President, Finance and Chief Financial Officer 372.8K 364.0K 492.5K 250.0K 18.9K 1.50M 49.56%
185 2001 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 593.8K 642.0K 23.8K 79.6K 1.34M 1.78%
186 2001 Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer 372.8K 364.0K 492.5K 90.0K 18.9K 1.34M 43.53%
187 2001 William G. Dempsey Senior Vice President, Pharmaceutical Operations 437.7K 525.0K 90.0K 90.3K 1.14M 7.87%
188 2001 William G. Dempsey Senior Vice President, International Operations 437.7K 525.0K 89.7K 90.3K 1.14M 7.85%
189 2001 Christopher B. Begley Senior Vice President, Hospital Products 430.4K 425.0K 70.0K 128.5K 1.05M 6.64%
190 2000 Robert L. Parkinson Jr. Retired President, and Chief Operating Officer 982.8K 1.09M 350.0K 4.41M 6.83M 5.12%
191 2000 Jeffrey M. Leiden, M.D., Ph.D. President and Chief Operating Officer, Pharmaceutical Products Group and Director 276.3K 555.0K 3.18M 250.0K 114.3K 4.38M 78.40%
192 2000 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.39M 1.80M 223.3K 132.8K 3.55M 6.30%
193 2000 Richard A. Gonzalez Executive Vice President, Medical Products 469.7K 517.0K 767.2K 167.1K 54.4K 1.98M 47.30%
194 2000 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 469.7K 517.0K 767.2K 52.0K 54.4K 1.86M 44.04%
195 2000 Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer 498.9K 500.0K 250.0K 446.6K 1.70M 14.74%
196 2000 Joy A. Amundson Senior Vice President, Ross Products 428.9K 436.0K 346.9K 70.0K 111.1K 1.39M 29.93%
197 2000 William G. Dempsey Senior Vice President, International Operations 399.2K 435.0K 120.0K 56.1K 1.01M 11.88%
198 2000 Christopher B. Begley Senior Vice President, Hospital Products 356.4K 353.0K 10.0K 86.9K 806.3K 1.24%
199 2000 Thomas C. Freyman Senior Vice President, Finance and Chief Financial Officer 252.4K 232.0K 100.0K 14.1K 598.5K 16.71%
200 1999 Miles D. White Chairman of the Board, Chief Executive Officer and Director 1.31M 800.0K 450.0K 95.7K 2.65M 16.97%
201 1999 Robert L. Parkinson Jr. Retired President, and Chief Operating Officer 932.7K 600.0K 57.8K 76.6K 1.67M 3.47%
202 1999 Christopher B. Begley Senior Vice President, Hospital Products 296.2K 222.7K 760.0K 250.0K 54.6K 1.58M 63.79%
203 1999 Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer 480.4K 384.3K 133.7K 309.1K 1.31M 10.23%
204 1999 Richard A. Gonzalez President and Chief Operating Officer, Medical Products Group and Director 366.3K 315.0K 250.0K 37.1K 968.4K 25.82%
205 1999 Joy A. Amundson Senior Vice President, Ross Products 412.4K 370.0K 95.8K 75.6K 953.7K 10.04%
206 1999 Richard A. Gonzalez Executive Vice President, Medical Products 366.3K 315.0K 90.0K 37.1K 808.4K 11.13%
207 1999 William G. Dempsey Senior Vice President, International Operations 322.4K 220.0K 100.0K 30.0K 672.4K 14.87%
208 1998 Miles D. White Chairman of the Board, Chief Executive Officer and Director 669.6K 1.00M 740.0K 89.9K 45.4K 2.54M 32.61%
209 1998 Robert L. Parkinson Jr. Retired President, and Chief Operating Officer 598.5K 700.0K 740.0K 325.0K 51.2K 2.41M 44.11%
210 1998 Richard A. Gonzalez Executive Vice President, Medical Products 308.6K 300.0K 1.04M 23.0K 33.1K 1.70M 62.27%
211 1998 Joy A. Amundson Senior Vice President, Ross Products 382.7K 360.0K 740.0K 80.0K 65.1K 1.63M 50.37%
212 1998 Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer 463.8K 465.0K 320.0K 276.6K 1.53M 20.98%
213 1998 William G. Dempsey Senior Vice President, International Operations 263.8K 220.0K 962.0K 26.6K 10.3K 1.48M 66.68%
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-03-13 DEFA14A
2026-03-13 DEF 14A

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-27 SD
2026-04-29 SC 13G
2026-04-29 4
2026-04-29 10-Q
2026-04-28 4
2026-04-28 4
2026-04-28 4
2026-04-28 4
2026-04-28 4
2026-04-28 4

Executive team

NameTitleCompensationGender
Robert Ford Chairman, Pres & Chief Executive Officer 4M male
Elizabeth Cushman Executive Vice President, General Counsel & Secretary 3M female
Lisa D. Earnhardt Executive Vice President & Group President of Medical Devices 2M female
Philip Boudreau Chief Financial Officer & Executive Vice President of Finance 2M male
Christopher J. Scoggins Executive Vice President of Diabetes Care 2M male
Daniel Gesua Sive Salvadori Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products 2M male
Sabina Ewing Senior Vice President of Business & Technology Services and Chief Information Officer female
Erica L. Battaglia Vice President and Chief Ethics & Compliance Officer
Melissa Brotz Senior Vice President of Global Marketing & External Affairs female
Michael Comilla Vice President of Investor Relations. male
ESG Rating
B
MEDICAL - DEVICES
2003
E (Environmental)
66.7 / 62.5
Company / Sector avg.
S (Social)
60.1 / 68.9
Company / Sector avg.
G (Governance)
67.7 / 64.8
Company / Sector avg.
ESG Total
64.8 / 65.4
Company / Sector avg.
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2025-02-24 2025-03-06 Shelley Moore Capito WV Spouse Sale (Partial) $1,001 - $15,000
2025-01-08 2025-01-31 Markwayne Mullin OK Joint Sale (Full) $1,001 - $15,000
2024-12-11 2024-12-31 Markwayne Mullin OK Joint Sale (Partial) $15,001 - $50,000
2024-01-17 2024-02-02 Thomas R. Carper DE Spouse Sale (Partial) $1,001 - $15,000
2023-10-03 2023-11-01 Markwayne Mullin OK Joint Purchase $1,001 - $15,000
2023-09-21 2023-10-20 Pete Ricketts NE Spouse Sale (Full) $100,001 - $250,000
2023-09-13 2023-10-12 Markwayne Mullin OK Joint Purchase $15,001 - $50,000
2022-10-17 2022-11-03 Thomas R. Carper DE Spouse Purchase $1,001 - $15,000
2020-04-07 2020-05-01 Kelly Loeffler GA Spouse Purchase $1,001 - $15,000
2020-03-03 2020-04-29 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2019-04-09 2019-04-24 Tina Smith MN Joint Sale (Full) $250,001 - $500,000
2018-04-24 2019-05-09 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2018-04-05 2018-05-14 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2017-10-24 2018-10-26 Bill Cassidy LA Spouse Sale (Partial) $1,001 - $15,000
2017-10-18 2017-11-07 Tammy Duckworth IL Joint Sale (Full) $1,001 - $15,000
2017-02-23 2017-03-15 Sheldon Whitehouse RI Joint Sale (Full) $1,001 - $15,000
2016-11-15 2016-12-12 Sheldon Whitehouse RI Joint Purchase $1,001 - $15,000
2016-04-19 2016-05-04 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
2016-03-31 2017-12-06 Bill Cassidy LA Spouse Purchase $1,001 - $15,000
2015-07-21 2015-08-03 Shelley Moore Capito WV Spouse Purchase $1,001 - $15,000
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2026-03-24 2026-04-20 Laura Friedman Exchange $1,001 - $15,000
2026-03-19 2026-04-07 Richard Dean Dr McCormick GA06 Purchase $1,001 - $15,000
2026-03-04 2026-04-10 Michael McCaul TX10 Spouse Sale $1,001 - $15,000
2026-02-10 2026-03-10 Gilbert Cisneros CA31 Sale $1,001 - $15,000
2026-01-29 2026-02-20 Thomas H. Kean NJ07 Purchase $1,001 - $15,000
2025-12-19 2026-01-12 Gilbert Cisneros CA31 Sale (Partial) $1,001 - $15,000
2025-12-18 2026-01-16 Julie Johnson TX32 Joint Sale $1,001 - $15,000
2025-12-08 2026-01-13 Julia Letlow LA05 Sale (Full) $1,001 - $15,000
2025-12-04 2026-01-08 Byron Donalds FL19 Sale $1,001 - $15,000
2025-11-18 2025-12-15 Gilbert Cisneros CA31 Purchase $1,001 - $15,000
2025-11-13 2025-12-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000
2025-11-05 2025-12-10 Rich McCormick Purchase $1,001 - $15,000
2025-10-30 2025-11-14 Ro Khanna CA17 Sale $1,001 - $15,000
2025-10-06 2025-10-17 Rick Larsen WA02 Purchase $1,001 - $15,000
2025-08-14 2025-09-12 Julie Johnson TX32 Joint Sale $1,001 - $15,000
2025-08-06 2025-09-12 Ro Khanna CA17 Sale $1,001 - $15,000
2025-07-21 2025-08-21 Thomas H. Kean NJ07 Purchase $1,001 - $15,000
2025-07-18 2025-08-12 Josh Gottheimer NJ05 Joint Sale $1,001 - $15,000
2025-07-10 2025-08-13 Lisa McClain MI09 Spouse Sale (Full) $1,001 - $15,000
2025-07-10 2025-08-14 Lisa McClain MI09 Spouse Sale $1,001 - $15,000
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits